Biomarker for predicting curative effect of lung squamous cell carcinoma immune combined chemotherapy and application of biomarker

Abstract

The invention discloses a biomarker for predicting the curative effect of lung squamous cell carcinoma immune combined chemotherapy and application of the biomarker. The biomarker comprises any one of hsa-miR-610, hsa-miR-4536-5p, hsa-miR-204-5p, hsa-miR-5196-3p, hsa-miR-6513-5p or hsa-miR-143-3p or a combination of at least two of the hsa-miR-610, the hsa-miR-4536-5p, the hsa-miR-204-5p, the hsa-miR-5196-3p, the hsa-miR-6513-5p and the According to the invention, expression difference of plasma exosome miRNA in patients with good prognosis and poor prognosis of advanced lung squamous cell carcinoma on immune combined chemotherapy is analyzed through small RNA sequencing, modeling is carried out, a biomarker which can be used for prediction of curative effect of lung squamous cell carcinoma immune combined chemotherapy and screening of beneficial people is screened, and prediction efficiency of the combined model is verified at the same time. A non-invasive detection solution is provided aiming at how to more conveniently and accurately distinguish the immune combined chemotherapy benefit people and the benefit-deficient people.